Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03614364 | Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma | unknown | Phase 2 | 41 | Samsung Medical CenterOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05177237 | Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma | unknown | Phase 2 | 30 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT04282070 |
| SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma |
| unknown |
| Phase 1 |
| 91 |
| Jiangsu HengRui Medicine Co., Ltd.INDUSTRY |
| 1 |
| Dec 21, 2021 |
| clinicaltrials |
| NCT05162872 | Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 99 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | unknown | Phase 1 / Phase 2 | 401 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05136768 | Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)(LM-HNSCC) | unknown | Phase 2 | 50 | Jun-Lin Yi, MDUNKNOWN | 1 | Nov 29, 2021 | clinicaltrials |
| NCT05117138 | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | unknown | Phase 1 / Phase 2 | 39 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 11, 2021 | clinicaltrials |
| NCT05112510 | Prognostic Prediction of NPC Based on MR Diffusion-weighted Imaging | unknown | — | 125 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT04367909 | A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma | unknown | Phase 2 | 68 | Xin-Hua XuOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT03291002 | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | unknown | Phase 1 | 98 | CureVacINDUSTRY | 5 | Nov 4, 2021 | clinicaltrials |
| NCT04650633 | SHR-1701 in Patients With Recurrent/Metastatic Scchn | unknown | Phase 2 | 130 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05092217 | Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 80 | Eye & ENT Hospital of Fudan UniversityOTHER | 0 | Oct 25, 2021 | clinicaltrials |
| NCT02041260 | A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting | unknown | Phase 2 | 43 | Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT03843515 | Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction(NeoNivo) | unknown | Phase 1 | 17 | Amsterdam UMC, location VUmcOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT05065086 | Single Modality Trans Oral Robotic Surgery for Primary Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence(STORM) | unknown | — | 500 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT03942380 | Cell-free Tumor DNA in Head and Neck Cancer Patients | unknown | N/A | 500 | Christian von BuchwaldOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT02512315 | A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma | unknown | Phase 3 | 192 | Sun Yat-sen UniversityOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT05024019 | Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery | unknown | Phase 2 | 95 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT05020925 | SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2021 | clinicaltrials |
| NCT03668730 | Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 | 215 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04992988 | Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial | unknown | Phase 2 | 40 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT05013515 | Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas | unknown | N/A | 20 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT05008796 | PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT | unknown | — | 50 | Chang Gung Memorial HospitalOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT04999800 | Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1 | unknown | Phase 2 | 20 | Shi YuankaiUNKNOWN | 1 | Aug 11, 2021 | clinicaltrials |
| NCT03450967 | Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC | unknown | Phase 2 | 31 | Samsung Medical CenterOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04955886 | Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 14 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03904225 | Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis | unknown | Phase 2 | 220 | Zhejiang Cancer HospitalOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04916262 | Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer | unknown | — | 160 | Qianfoshan HospitalOTHER | 0 | Jun 16, 2021 | clinicaltrials |
| NCT04917770 | The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 28 | West China HospitalOTHER | 0 | Jun 8, 2021 | clinicaltrials |
| NCT04270201 | Determination of ALDH1b1 and ALDH2 Polymorphisms Frequency in the Brazilian Population(ALDH2020) | unknown | — | 300 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04882462 | Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.(Carpp-1) | unknown | Phase 2 | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | May 12, 2021 | clinicaltrials |
| NCT03134846 | Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate(ICON) | unknown | Phase 1 / Phase 2 | 79 | University Medical Center GroningenOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT04867330 | Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC | unknown | N/A | 46 | Fudan UniversityOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04745741 | Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC | unknown | — | 200 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 29, 2021 | clinicaltrials |
| NCT04861467 | Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 155 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04523883 | Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)(IMPORT) | unknown | Phase 2 | 316 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT02661152 | DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.(DAHANCA30) | unknown | Phase 3 | 1,252 | Danish Head and Neck Cancer GroupNETWORK | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04196985 | 18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC(HENEPET) | unknown | N/A | 40 | Turku University HospitalOTHER_GOV | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04832555 | Non Elective Vulnerable Elderly Radiotherapy(NEVER) | unknown | N/A | 100 | Azienda Ospedaliero Universitaria Policlinico ModenaOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04826679 | Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC | unknown | Phase 2 | 53 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04801264 | Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 | unknown | Early Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT04810936 | Early Nutritional Intervention in NPC Patients Undergoing Concurrent Chemoradiotherapy | unknown | N/A | 272 | Guangdong Provincial People's HospitalOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT03771820 | Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen | unknown | Phase 2 | 136 | NanoCarrier Co., Ltd.INDUSTRY | 8 | Mar 17, 2021 | clinicaltrials |
| NCT02054442 | A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck(COMMENCE) | unknown | Phase 1 / Phase 2 | 52 | Radboud University Medical CenterOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT04780750 | Concurent Chemoradiotherapy in Head and Neck Cancers | unknown | Phase 3 | 60 | Assiut UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT04769076 | The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Feb 25, 2021 | clinicaltrials |
| NCT04766359 | Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma | unknown | Phase 3 | 364 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Feb 23, 2021 | clinicaltrials |
| NCT04766827 | Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor | unknown | Phase 4 | 116 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04764149 | Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma | unknown | — | 801 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jan 4, 2022source: clinicaltrials